Last reviewed · How we verify

NCT06929559: SYAMAPP

Muscular Synergies and Behavioral Adaptations of Gait in Pain Anticipation (SYAMAPP)

Not yet recruiting NA Last updated 26 September 2025
What this trial tests

NA trial testing Pain expectation conditioning in Nocebo Effect in 34 participants. Not yet recruiting.

Timeline
1 October 2025
Primary endpoint
30 October 2025
30 October 2028

Quick facts

Lead sponsorUniversite de Picardie Jules Verne
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposebasic science
Enrollment34
Start date1 October 2025
Primary completion30 October 2025
Estimated completion30 October 2028
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Universite de Picardie Jules Verne

Who can join

Adults 18 to 35, any sex, with Nocebo Effect or Pain Anticipation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether the anticipation of pain influences gait control and psychophysiological responses in healthy individuals. Participants will receive a neutral cream described either as potentially painful (experimental group) or inert (control group), and their behavioral and physiological adaptations will be measured during walking tasks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Pain expectation conditioning

Trials testing the same drug.

Other Universite de Picardie Jules Verne trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06929559.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing